{"nctId":"NCT01856543","briefTitle":"Mometasone Furoate 0.1% Versus Eucerin on Moderate to Severe Skin Toxicities in Breast Cancer Patients Receiving Postmastectomy Radiation","startDateStruct":{"date":"2013-05","type":"ACTUAL"},"conditions":["Invasive Breast Cancer"],"count":143,"armGroups":[{"label":"Eucerin","type":"PLACEBO_COMPARATOR","interventionNames":["Other: Eucerin"]},{"label":"Mometasone Furoate 0.1%","type":"EXPERIMENTAL","interventionNames":["Other: Mometasone Furoate 0.1%"]}],"interventions":[{"name":"Eucerin","otherNames":[]},{"name":"Mometasone Furoate 0.1%","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Age â‰¥18 years\n* Stage 1-4 invasive breast cancer that is histologically confirmed at MSKCC\n* Status post mastectomy with axillary exploration (sentinel node biopsy and/or axillary lymph node dissection) to receive PMRT\n* ECOG Performance Status of 0 or 1\n\nExclusion Criteria:\n\n* Male\n* Patients with clinical evidence of gross disease\n* Patients who are pregnant or breastfeeding\n* Prior radiation therapy to the ipsilateral chest wall or thorax\n* Patients requiring a chest wall boost\n* Concurrent chemotherapy (biologic agents are allowed)\n* Psychiatric illness that would prevent the patient from giving informed consent\n* Inability or unwillingness to comply with skin care instructions and follow-up\n* Allergy to either Eucerin or MF\n* Residual grade \\>1 skin toxicity, cellulitis, or incompletely healed wound(s) at intended site of study drug application at the time of the start of RT\n* Medical condition such as uncontrolled infection (including HIV), uncontrolled diabetes mellitus, or connective tissue diseases (lupus, systemic sclerosis, or other collagen vascular diseases)\n* Treatment with palliative or pre-operative radiation","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Moist Desquamation","description":"Skin toxicity assessments will be done on a weekly basis while the patient is receiving RT, by the RN or physician utilizing CTCAE 4.0 and the weekly status check form, as per current standard practice.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"66.7","spread":null},{"groupId":"OG001","value":"43.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Difference From Baseline and 5 Weeks Between Patient-reported Skin Toxicities at Baseline and End of Radiation Treatment","description":"The Skindex-16 assessment tool is designed to capture patient-reported assessments of subjective adverse effects. It consists of a short 16-item assessment completed by the patient, with each item rated on a 7-point Likert scale (0=never bothered to 6=always bothered). Responses to the Skindex-16 are categorized into three subscales: symptom, emotional, and functional. Scores for the emotions, symptoms and functioning scales are also expressed in a linear scale from 0 to 100. Rankings of the questionnaire are then averaged to obtain a score of severity of patient-reported outcomes. This allows providers to gauge which aspects of the participant's experience are most affected by the treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.0","spread":"11.4"},{"groupId":"OG001","value":"5.0","spread":"9.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.0","spread":"7.2"},{"groupId":"OG001","value":"6.0","spread":"6.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","spread":"7.4"},{"groupId":"OG001","value":"1.0","spread":"5.3"}]}]}]},{"type":"SECONDARY","title":"Difference Between Patient-reported Skin Toxicities at End of Radiation Therapy and 2 Week Follow-up","description":"The Skindex-16 assessment tool is designed to capture patient-reported assessments of subjective adverse effects. It consists of a short 16-item assessment completed by the patient, with each item rated on a 7-point Likert scale (0=never bothered to 6=always bothered). Responses to the Skindex-16 are categorized into three subscales: symptom, emotional, and functional. Scores for the emotions, symptoms and functioning scales are also expressed in a linear scale from 0 to 100. Rankings of the questionnaire are then averaged to obtain a score of severity of patient-reported outcomes. This allows providers to gauge which aspects of the participant's experience are most affected by the treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.0","spread":"12.3"},{"groupId":"OG001","value":"12.0","spread":"12.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.0","spread":"7.4"},{"groupId":"OG001","value":"11.0","spread":"6.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.0","spread":"7.9"},{"groupId":"OG001","value":"5.0","spread":"9.1"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":73},"commonTop":["Lymphocyte count decreased","White blood cell decreased","Dermatitis radiation","Neutrophil count decreased","Anemia"]}}}